In prostate cancer, miR-466, by directly repressing the osteogenic transcription factor RUNX2, inhibits tumor growth and metastases [35], highlighting the role of RUNX2 in inducing the malignant phenotype. This evidence concerns the gene RUNX2 and prostate carcinoma.